Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Next Article in Journal
Home-Based Exercise Training and Cardiac Autonomic Neuropathy in Kidney Transplant Recipients with Type-II Diabetes Mellitus
Next Article in Special Issue
A Literature Review on the Use of Aortic Allografts in Modern Cardiac Surgery for the Treatment of Infective Endocarditis: Is There Clear Evidence or Is It Merely a Perception?
Previous Article in Journal
Pharmacological Properties of Chemically Characterized Extracts from Mastic Tree: In Vitro and In Silico Assays
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 6
10.3390/life13061395
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Role of «Novel» Biomarkers of Systemic Inflammation in the Development of Early Hospital Events after Aortic Valve Replacement in Patients with Aortic Stenosis

by
Vladimir Shvartz
1,*,
Maria Sokolskaya
1,
Artak Ispiryan
1,
Madina Basieva
1,
Polina Kazanova
1,
Elena Shvartz
2,
Sayali Talibova
1,
Andrey Petrosyan
1,
Teymuraz Kanametov
1,
Sergey Donakanyan
1,
Leo Bockeria
1 and
Elena Golukhova
1
1
Bakulev National Medical Research Center for Cardiovascular Surgery, Moscow 121552, Russia
2
National Medical Research Center for Therapy and Preventive Medicine, Moscow 101990, Russia
*
Author to whom correspondence should be addressed.
Life 2023, 13(6), 1395; https://doi.org/10.3390/life13061395
Submission received: 10 May 2023 / Revised: 25 May 2023 / Accepted: 13 June 2023 / Published: 14 June 2023
(This article belongs to the Special Issue Advances and Applications of Cardiac Surgery)
Browse Figures
Review Reports Versions Notes

Abstract

:
Introduction. The pathogenesis of aortic stenosis includes the processes of chronic inflammation, calcification, lipid metabolism disorders, and congenital structural changes. The goal of our study was to determine the predictive value of novel biomarkers of systemic inflammation and some hematological indices based on the numbers of leukocytes and their subtypes in the development of early hospital medical conditions after mechanical aortic valve replacement in patients with aortic stenosis. Materials and methods. This was a cohort study involving 363 patients who underwent surgical intervention for aortic valve pathology between 2014 and 2020. The following markers of systemic inflammation and hematological indices were studied: SIRI (Systemic Inflammation Response Index), SII (Systemic Inflammation Index), AISI (Aggregate Index of Systemic Inflammation), NLR (Neutrophil/Lymphocyte Ratio), PLR (Platelet/Lymphocyte Ratio), and MLR (Monocyte/Lymphocyte Ratio). Associations of the levels of these biomarkers and indices with the development of in-hospital death, acute kidney injury, postoperative atrial fibrillation, stroke/acute cerebrovascular accident, and bleeding were calculated. Results. According to an ROC analysis, an SIRI > 1.5 (p < 0.001), an SII > 718 (p = 0.002), an AISI > 593 (p < 0.001), an NLR > 2.48 (p < 0.001), a PLR > 132 (p = 0.004), and an MLR > 0.332 (p < 0.001) were statistically significantly associated with in-hospital death. Additionally, an SIRI > 1.5 (p < 0.001), an NLR > 2.8 (p < 0.001), and an MLR > 0.392 (p < 0.001) were associated with bleeding in the postoperative period. In a univariate logistic regression, SIRI, SII, AISI, and NLR were statistically significant independent factors associated with in-hospital death. In a multivariate logistic regression model, SIRI was the most powerful marker of systemic inflammation. Conclusion. SIRI, SII, AISI, and NLR as novel biomarkers of systemic inflammation were associated with in-hospital mortality. Of all markers and indices of systemic inflammation in our study, SIRI was the strongest predictor of a poor outcome in the multivariate regression model.

Graphical Abstract

1. Introduction

Aortic valve stenosis is one of the most common cardiovascular diseases requiring surgical intervention. The incidence of this condition increases with age, and among patients over 65 years old, this condition is diagnosed in 2–5% of cases [1,2]. The pathogenesis of aortic stenosis involves processes of chronic inflammation, calcification, lipid metabolism disorders, and congenital structural changes [3].
Despite advances in medical science, along with the development of diagnostic and laboratory methods and pharmaceutical drugs, it is currently impossible to prevent the development and progression of this defect using modern medicamentous treatments. The most commonly performed surgery for aortic stenosis at present is aortic valve replacement in conditions of artificial blood circulation [4]. The mortality during isolated aortic valve repair does not exceed 3% [5]. In most cases, the risk of postoperative complications and death after surgery is associated with the preoperative comorbid status of the patient. Therefore, identifying predictors of unfavorable course development in the perioperative period is essential.
Preoperative and intraoperative risk factors have been well studied and defined. The former include age, reduced contractile capacity of the left ventricular myocardium, diagnosed diabetes mellitus, kidney and liver failure, arrhythmias, and stenotic coronary atherosclerosis. The latter comprise cardiopulmonary bypass time, aortic cross-clamp time, and the extent of the surgical intervention [6]. However, the search for other risk factors continues, because their early detection and correction can improve treatment outcomes.
To date, the prognostic significance of the so-called “novel” biomarkers of systemic inflammation in patients with various cardiovascular pathologies and chronic vascular diseases is actively studied [7,8,9]. These include the Systemic Inflammation Response Index (SIRI), the Systemic Inflammation Index (SII), the Aggregate Index of Systemic Inflammation (AISI), and various hematological indices based on the numbers of leukocytes and their subtypes (neutrophils, lymphocytes, and monocytes) [10,11,12]. However, there are few published studies which have investigated the possibility of using these biomarkers and indices in patients with acquired heart valve defects. Since these parameters of systemic inflammation are easily reproducible and potentially informative, we conducted this study.
The objective of our study was to examine the predictive value of novel biomarkers of systemic inflammation and some hematological indices based on the numbers of leukocytes and their subtypes in the development of early hospital medical conditions after mechanical aortic valve replacement in patients with aortic stenosis.

2. Materials and Methods

2.1. Study Population

This study consists of a subanalysis of the database that includes all patients who underwent surgical intervention for aortic valve pathology in the cardiac surgery department at Bakulev Scientific Center of Cardiovascular Surgery. The general database encompasses patients with surgical aortic valve replacement (SAVR), mechanical and biological prostheses, transcatheter aortic valve replacement (TAVR), reconstructive aortic valve sparing operations, etc. The causes of aortic valve pathology in patients included in the general database are both congenital anomalies (bicuspid aortic valve) and acquired disorders (defects of rheumatic etiology, degenerative valve disease, infective endocarditis, etc.).
This article includes an analysis of the hospital stay (2014–2020) in patients who underwent aortic valve replacement with a mechanical prosthesis. Hemodynamically, these were patients with predominant aortic valve stenosis. Previously, we identified the clinical predictors of mortality in the early postoperative period in this cohort of patients [13].
For this analysis, the following pathologies were excluded from the database: concomitant pathologies of the mitral and tricuspid valves, ischemic heart disease, any arrhythmias including a history of atrial fibrillation, previous stroke, and any oncological disease including benign tumors. The patients were from the same department, and all of them underwent similar surgeries (with retrograde cardioplegia).

2.2. Data Collection

Standard examination before surgery included the collection of clinical and anamnestic data, along with laboratory and instrumental tests. Confirmation of accompanying comorbid pathology was carried out by a physician specialized in the particular field (for example, an endocrinologist for diabetes, a pulmonologist for COPD, etc.). Confirmation or exclusion of ischemic heart disease was performed in all patients over 40 years old using selective coronary angiography. Transthoracic echocardiography was performed on a daily basis in all patients prior to the operation and in the early postoperative period in order to assess hemodynamics, the presence of pericardial effusion, myocardial contractile function, etc. Laboratory diagnostics included evaluation of blood parameters before the operation, as well as daily for 5 days after the operation and additionally on the day of discharge from the clinic (usually 7–8 days after the operation). ECG monitoring in the clinic was carried out in the first few days after the surgery using bedside monitors, and then using long-term ECG Holter monitoring until discharge. Intraoperative data, intensive care unit (ICU) data, and early postoperative period data were collected from the general electronic database of the MedWork clinic in compliance with all legal requirements.
Our research protocol conformed to the ethical recommendations of the Helsinki Declaration of 1975 and the Ethical Recommendations of the Government of the Russian Federation on Conducting Epidemiological Studies. This study was approved by the Local Ethics Committee of the Bakulev Center for Cardiovascular Surgery. Informed written consent from each patient before each procedure was obtained.

2.3. Definitions

Indices of systemic inflammation were calculated using the following formulas: SIRI (Systemic Inflammation Response Index) = neutrophil count × monocyte count ÷ lymphocyte count; SII (Systemic Inflammation Index) = neutrophil count × platelet count ÷ lymphocyte count; AISI (Aggregate Index of Systemic Inflammation) = neutrophil count × monocyte count × platelet count ÷ lymphocyte count; NLR (Neutrophil/Lymphocyte Ratio) = neutrophil count ÷ lymphocyte count; PLR (Platelet/Lymphocyte Ratio) = platelet count ÷ lymphocyte count; and MLR (Monocyte/Lymphocyte Ratio) = monocyte count ÷ lymphocyte count.
Development of acute kidney injury (AKI) was diagnosed based on KDIGO criteria (Kidney Disease Improving Global Outcomes) either given an increase in the level of blood serum creatinine of ≥0.3 mg/dL (≥26.5 mmol/L) within 48 h, or given its increase of ≥1.5-fold over the baseline value within 7 days. Postoperative atrial fibrillation (POAF) development was identified via both long-term ECG Holter monitoring and standard 12-lead ECG to determine the absence of visible regular P waves, the emergence of F waves, or irregular RR intervals on an ECG for over 30 s in the postoperative period.
A stroke was diagnosed on the basis of clinical data, the results of a CT scan of the brain, or an entry in the anamnesis made by a neurologist about a complication that took place. Bleeding was considered as an acute blood loss in the early postoperative period if a patient required infusion of blood components (plasma or red blood cells).

2.4. Endpoints

The primary endpoint was in-hospital mortality. Secondary endpoints were the development of the following non-fatal events: AKI, POAF, stroke/acute cerebrovascular accident (ACA), and bleeding.

2.5. Surgery

Aortic valve replacement with a mechanical prosthesis was performed according to the standard procedure used in our department. All operations were performed in a planned manner in conditions of cardiopulmonary bypass, hypothermia, and pharmacological cold cardioplegia. Cardioplegia was performed retrogradely through the coronary sinus in all cases. A median sternum incision was used as an access to the heart. Combinations of aortic valve replacement with CABG, mitral valve interventions, and other manipulations were not considered in this article [14].

2.6. Statistical Analysis

The database included quantitative and qualitative variables. Quantitative data were tested for the normality of the distribution using the Shapiro–Wilk criterion. However, the distribution was always different from normal. To determine the effective diagnostic threshold values of the studied indices of systemic inflammation, we used an ROC analysis with curve construction and estimation of the area under the curve (AUC). The relationship between hospital mortality and the studied risk factors was assessed using single-factor and multivariate logistic regression analyses and represented by the odds ratio (OR), 95% confidence interval (CI), and p-value.
The data are presented in the form of median (Me) and interquartile range (Q1; Q3) when describing quantitative parameters, as well as in the form of an absolute number (n) and the fractional value (%) when describing qualitative parameters. In this analysis, we used the following software: Microsoft Office Excel and MedCalc (MedCalc Software Ltd., Ostend, Belgium).

3. Results

Our study encompassed 363 patients: 221 men (61%) and 142 women (39%). Their median age was 58.5 (44; 66.7) years. Table 1 presents the baseline clinical, initial instrumental, and initial laboratory characteristics of patients and their drug therapy before surgery. The operative data of patients and hospital outcomes of patients are presented in Table 2.
An ROC analysis was performed to determine threshold values for systemic inflammation indices associated with the primary and secondary endpoints of the study (Table 3 and Figure 1).
When performing the univariate and multivariate logistic regression analyses, we also added clinical and operational predictors of a lethal outcome that we found earlier in this cohort of patients [13] (Table 4).

4. Discussion

This study included solely patients with isolated aortic stenosis in accordance with our inclusion/exclusion criteria. We initially limited the potential impact of other pathologies by excluding patients with concomitant pathology of other heart valves, ischemic heart disease, arrhythmias, and cancer from the analysis. Consequently, as can be seen from Table 1, the severity of concomitant pathology was insignificant. The frequency of the primary endpoint (in-hospital mortality) was 2% (seven patients). The frequencies of secondary endpoints in this study were as follows: 13% for AKI, 10% for POAF, 2% for stroke/ACA, and 0.8% for bleeding.
In the course of the ROC analysis, statistically significant threshold values associated with the development of in-hospital mortality were obtained for all systemic inflammation indices. Statistically significant levels were also obtained for some of the studied indices associated with the development of bleeding in the early postoperative period. No statistically significant levels were observed for inflammation indices associated with the development of AKI, POAF, and stroke/ACA.
The univariate analysis revealed that novel biomarkers of systemic inflammation and NLR were statistically significant independent factors associated with in-hospital mortality. Some of the previously obtained operational data and the level of hemoglobin before the surgery had prognostic values as well. In the multivariable logistic regression analysis, only two factors were statistically significant (SIRI and ACC time), while all other factors were leveled off by the multifactorial nature of the model.
A number of studies have demonstrated that the level of neutrophils, lymphocytes, and platelets plays an important role in the development of chronic inflammation and the progression of cardiovascular diseases. In some studies, biomarkers such as C-reactive protein, NLR, and PLR demonstrated their prognostic values for the risk of postoperative complications and mortality [15,16,17]. For example, in the study by Russu E. et al., the preoperative role of NLR and PLR in the medium-term outcome of patients surgically revascularized for femoropopliteal disease was studied. It was shown that a high value of preoperative NLR and PLR determined at hospital admission was strongly predictive of primary patency failure (12 months after revascularization). Additionally, elevated ratio values are an independent predictor for a higher amputation rate [18].
In recent years, the possibility of using the SII as a predictor of unfavorable outcomes among patients with acquired heart defects was actively investigated. This marker of systemic inflammation takes into account the level of neutrophils, platelets, and lymphocytes, thereby reflecting both inflammatory and immunological activation, as well as activation of the coagulation cascade [17]. The SII was studied in patients with chronic heart failure, neoplasms, and nervous system disorders [7,8]. In addition, this index was found to be statistically significant for predicting adverse outcomes in scheduled myocardial revascularization, and also for predicting the frequency of POAF and other complications in the postoperative period in cardiac surgery patients [19,20,21]. Tosu et al. conducted a follow-up of 120 patients undergoing transcatheter aortic valve implantation (TAVI) for aortic stenosis, in whom the SII was an independent predictor of postoperative complications [22]. The study by Xiang J et al. analyzed a cohort of patients (n = 431) with various valve pathologies who underwent surgical intervention. It was established that a high level of preoperative systemic inflammation, measured with the SII, was statistically significantly associated with an increased risk of postoperative complications, the 30 day postoperative mortality, the duration of stay in the ICU, and the duration of the hospital stay [16].
Another marker of inflammation, the SIRI, combines neutrophils, monocytes, and lymphocytes in peripheral blood and is an indicator of low-grade chronic inflammation. Its elevated values are associated with the risk of developing a stroke, a complicated postoperative period, and a 5 year mortality rate after off-pump CABG surgery [23,24]. In our study, this parameter exhibited the strongest correlation with the primary endpoint.
The AISI is less studied and less common in the literature. It takes into account the ratio of all subtypes of leukocytes and platelets. Study [25] presented data that could be used as a predictor of a complicated postoperative period for thoracic surgery. However, this study had a relatively small sample size (157 patients), which limited the reliability of the obtained results. Among the published studies, we did not find any in which the AISI was analyzed for cardiac surgery. Therefore, further investigation of this marker in cardiac surgery is required.
The NLR was proposed as a straightforward marker of inflammation that is useful for the long-term prognosis in ischemic heart disease and as a prognostic risk factor for the development of postoperative complications, POAF, and mortality after cardiovascular surgery [26,27,28,29,30]. Neutrophils are participants of the inflammatory response. They can secrete inflammatory mediators and are involved in the processes of phagocytosis and chemotaxis. Activated neutrophils release genetic material, thereby forming chromatin networks known as neutrophil extracellular traps (NETs). The latter induce oxidative stress and dysfunction of endothelial cells, along with contributing to the accumulation of prothrombotic molecules [9,31,32]. These highly sensitive markers are difficult to identify in routine clinical practice, whereas an increase in the number of neutrophils in peripheral blood can be considered as a basic method for monitoring neutrophil activation [16]. Including the NLR in a prognostic model, along with clinical preoperative factors and echocardiographic parameters, can help identify a group of patients requiring more careful postoperative monitoring due to an increased risk of complications. In our study, the NLR was statistically significantly associated with in-hospital mortality in a univariate model.
Monocytes play an important role in the formation of atherosclerotic plaque. The interaction between monocytes and endothelial cells leads to a local imbalance between the processes of damage and repair, which negatively affects the stability of the plaque. In the literature, the MLR is considered as a risk factor for venous bypass patency after revascularization, as well as a marker of a poor 5 year prognosis after off-pump CABG [33,34,35]. Endothelial dysfunction plays an important role in the pathogenesis of aortic stenosis; thus, we examined the MLR in this cohort of patients. Although the ROC analysis identified diagnostic levels of MLR that were statistically significantly associated with in-hospital mortality and early bleeding, we did not obtain statistically significant data on this indicator in the regression analysis.
The PLR is considered as a prognostic risk factor for cardiovascular diseases and a marker of perioperative complications. Additionally, some studies established a correlation between the PLR and the severity of coronary artery lesions [36,37,38,39]. Platelets are formed from the mononuclear phagocyte system. They interact with leukocytes and endothelial cells of blood vessels; activate and induce adhesion and transport of monocytes; participate in the release of interleukin 1 (IL-1), tumor necrosis factor, and other factors of inflammation; and are involved in the processes of local myocarditis and myocardial fibrosis in patients with valve pathology [40]. An elevated level of platelets is associated with a poor prognosis for patients with cardiovascular disease [41]. Platelets participate in the onset of the atherosclerotic process and can maintain vascular inflammation. Additionally, they attract immune cells (monocytes and neutrophils), acting as mediators of tissue hemostasis, which can modulate the microenvironment of the atherosclerotic plaque [36,42,43]. Similar to the MLR, the PLR level in our study was statistically significant in the ROC analysis, but did not yield significance in the logistic regression.
A feature of the clinical picture of aortic stenosis is a long-term asymptomatic course of the defect. Therefore, many patients develop chronic heart failure, which triggers the processes of chronic inflammation, oxidative stress, and neurohormonal activation, leading to an increase in the level of cortisol in the blood plasma and the release of catecholamines. This suppresses lymphocyte differentiation and proliferation, followed by increased lymphocyte apoptosis [44]. Consequently, a reduced lymphocyte count is an independent predictor of poor survival in patients with chronic and progressive heart failure [45].
Currently, aortic valve replacement under the condition of a cardiopulmonary bypass (CPB) is the most commonly performed operation in this group of patients. Surgery under a CPB is a triggering factor for the development of an inflammatory response and increases the risk of complications. When choosing the strategy for surgical treatment of ischemic heart disease via open-heart surgery, preference is given to the off-pump technique, due to the undesirable side effects of a CPB during the on-pump technique [46]. For example, 70–90% of patients who underwent on-pump CABG were diagnosed with systemic inflammation [47]. The activation of a CPB triggers inflammatory processes and disrupts the endothelial function due to hemodilution, endothelial damage, hypothermia, nonpulsatile blood flow, administration of heparin, and the release of proinflammatory mediators. The inflammatory response associated with neutrophils can cause the activation of endothelial cells. In turn, endothelial cytotoxicity activates intracellular mechanisms for the production of nitric oxide. During a CPB, when an inflammatory response is generated, neutrophils are attracted to the site of tissue damage [48]. With a complex cascade of mediators, including tumor necrosis factor (TNF-α) and IL-1, endothelial and parenchyma cells are stimulated to release chemokines that attract neutrophils [49]. Adhesion and transmigration of neutrophils ultimately leads to transmigration into the extravascular space. Published sources have described systemic complications of a CPB such as platelet dysfunction, activation of the coagulation cascade, and production of free radicals [50].
Tissue damage involving neutrophils also occurs during reperfusion. Platelets and neutrophils may play a role in the so-called no reflow phenomenon, when they become trapped inside capillaries, causing hypoperfusion of hypoxic tissues [50,51]. Neutrophils are activated not only in the presence of a CPB. Contact of blood with a foreign surface triggers the activation of factor XII (FXII), with the formation of FXIIa and FXIIf [52]. Contact of the foreign body surface with blood components causes an inflammatory response. FXIIf is responsible for the activation of the complement system and complement membrane attack, lysis, and cell death. Endothelial cells produce procoagulant and anticoagulant factors that maintain hemorheology. Contoured artificial surfaces lead to the activation of coagulation cascades. Furthermore, thrombin and coagulation factor Xa, which are abundantly produced during CPB, activate platelets through their thrombin receptors of the PAR family and leukocytes [53]. In turn, activated platelets release neutrophil activators such as interleukins 6 and 8 (IL-6 and IL-8) [54]. Hence, coagulation is associated with the process of inflammation.
The inflammatory cell count in peripheral blood is used in clinical practice to predict the course of the postoperative period. Assessment of such indicators can improve the results of surgical treatment via better identification of patients with a higher risk of a poor outcome. Of course, further research is needed to establish the role of inflammation markers in specific groups of patients, taking into account the presence of diabetes mellitus, chronic kidney disease, and peripheral arterial disease.

Limitations of the Study

This analysis had disadvantages associated with the retrospective approach. Firstly, since all the data were collected from the general electronic database of our clinic MedWork with standard data entry, this does not exclude partial data loss. Secondly, a small number of patients were included in the analysis. However, this is explained by very strict inclusion and exclusion criteria. We excluded concomitant diseases, making the group more homogeneous in order to focus only on the effect of markers of systemic inflammation on the studied outcomes.

5. Conclusions

Elevated levels of novel biomarkers of systemic inflammation (SIRI, SII, and AISI), along with the level of the NLR, were associated with in-hospital mortality. Of all markers and indices of systemic inflammation in our study, the SIRI and CPB time were the strongest predictors of a poor clinical outcome in the multivariate regression model.
The possibility of the routine use of systemic inflammation indices for patients with aortic stenosis as predictors of the complications in the perioperative period is quite promising.

Author Contributions

Conceptualization, L.B. and E.G.; data curation, M.S., A.I., M.B., P.K., E.S. and S.T.; formal analysis, A.I., M.B., E.S., S.T., A.P. and T.K.; funding acquisition, V.S., M.S., A.I. and A.P.; investigation, V.S., M.S. and A.I.; methodology, V.S., A.P., L.B. and E.G.; project administration, V.S.; resources, V.S., P.K., T.K. and S.D.; software, M.S., P.K. and S.T.; supervision, S.T., T.K. and S.D.; visualization, A.I. and A.P.; writing—original draft, M.S., M.B., T.K. and S.D.; writing—review and editing, V.S., A.P., L.B. and E.G. All authors have read and agreed to the published version of the manuscript.

Funding

This trial was supported by the Russian Science Foundation, grant no. 18-74-10064.

Institutional Review Board Statement

This study was approved by the Ethics Committee of Bakulev Scientific Center for Cardiovascular Surgery (Protocol #7 of 4 April 2019).

Informed Consent Statement

Informed written consent from each patient before each procedure was obtained.

Data Availability Statement

The primary data analyzed in this study are not publicly available due to the policy of access to clinical data of the Bakulev Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation. However, some parameters that do not contain personal information can be provided by the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kopylova, N.S.; Sokol’skaya, N.O.; Skopin, I.I.; Kakhktsyan, P.V.; Asatryan, T.V. Possibilities and results of the method of intraoperative transesophageal echocardiography during Ozaki procedure. Creat. Cardiol. 2022, 16, 394–403. [Google Scholar] [CrossRef]
  2. Lindman, B.R.; Dweck, M.R.; Lancellotti, P.; Généreux, P.; Piérard, L.A.; O’Gara, P.T.; Bonow, R.O. Management of Asymptomatic Severe Aortic Stenosis: Evolving Concepts in Timing of Valve Replacement. JACC Cardiovasc. Imaging 2020, 13 Pt 1, 481–493. [Google Scholar] [CrossRef]
  3. Dayawansa, N.H.; Baratchi, S.; Peter, K. Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease. Front. Cardiovasc. Med. 2022, 9, 783543. [Google Scholar] [CrossRef]
  4. Muhamed, B.; Parks, T.; Sliwa, K. Genetics of rheumatic fever and rheumatic heart disease. Nat. Rev. Cardiol. 2020, 17, 145–154. [Google Scholar] [CrossRef]
  5. Grimard, B.H.; Safford, R.E.; Burns, E.L. Aortic Stenosis: Diagnosis and Treatment. Am. Fam. Physician 2016, 93, 371–378. [Google Scholar]
  6. Ambler, G.; Omar, R.Z.; Royston, P.; Kinsman, R.; Keogh, B.E.; Taylor, K.M. Generic, simple risk stratification model for heart valve surgery. Circulation 2005, 112, 224–231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Seo, M.; Yamada, T.; Morita, T.; Furukawa, Y.; Tamaki, S.; Iwasaki, Y.; Kawasaki, M.; Kikuchi, A.; Kawai, T.; Ikeda, I.; et al. P589 Prognostic value of systemic immune-inflammation index in patients with chronic heart failure. Eur. Heart J. 2018, 39, 70. [Google Scholar] [CrossRef]
  8. Hayıroğlu, M.; Çınar, T.; Çinier, G.; Pay, L.; Yumurtaş, A.; Tezen, O.; Eren, S.; Kolak, Z.; Çetin, T.; Çiçek, V.; et al. Evaluating systemic immune-inflammation index in patients with implantable cardioverter defibrillator for heart failure with reduced ejection fraction. Pacing Clin. Electrophysiol. 2022, 45, 188–195. [Google Scholar] [CrossRef] [PubMed]
  9. Bonaventura, A.; Montecucco, F.; Dallegri, F.; Carbone, F.; Lüscher, T.F.; Camici, G.G.; Liberale, L. Novel findings in neutrophil biology and their impact on cardiovascular disease. Cardiovasc. Res. 2019, 115, 1266–1285. [Google Scholar] [CrossRef]
  10. Arbănași, E.M.; Mureșan, A.V.; Coșarcă, C.M.; Kaller, R.; Bud, T.I.; Hosu, I.; Voidăzan, S.T.; Arbănași, E.M.; Russu, E. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Impact on Predicting Outcomes in Patients with Acute Limb Ischemia. Life 2022, 12, 822. [Google Scholar] [CrossRef]
  11. Melinte, R.M.; Arbănași, E.M.; Blesneac, A.; Zolog, D.N.; Kaller, R.; Mureșan, A.V.; Arbănași, E.M.; Melinte, I.M.; Niculescu, R.; Russu, E. Inflammatory Biomarkers as Prognostic Factors of Acute Deep Vein Thrombosis Following the Total Knee Arthroplasty. Medicina 2022, 58, 1502. [Google Scholar] [CrossRef] [PubMed]
  12. Kaller, R.; Arbănași, E.M.; Mureșan, A.V.; Voidăzan, S.; Arbănași, E.M.; Horváth, E.; Suciu, B.A.; Hosu, I.; Halmaciu, I.; Brinzaniuc, K.; et al. The Predictive Value of Systemic Inflammatory Markers, the Prognostic Nutritional Index, and Measured Vessels’ Diameters in Arteriovenous Fistula Maturation Failure. Life 2022, 12, 1447. [Google Scholar] [CrossRef]
  13. Shvartz, V.; Sokolskaya, M.; Petrosyan, A.; Ispiryan, A.; Donakanyan, S.; Bockeria, L.; Bockeria, O. Predictors of Mortality Following Aortic Valve Replacement in Aortic Stenosis Patients. Pathophysiology 2022, 29, 106–117. [Google Scholar] [CrossRef]
  14. Bockeria, L.A.; Bockeria, O.L.; Sanakoev, M.K.; Le, T.G.; Satyukova, A.S.; Ispiryan, A.Y.; Klimchuk, I.Y.; Fatulaev, Z.F.; Petrosyan, A.D.; Shvartz, V.A. Simultaneous surgical correction of atrial fibrillation and aortic valve replacement: Immediate results after surgery. Russ. Open Med. J. 2016, 5, 404. [Google Scholar] [CrossRef] [Green Version]
  15. Zhang, Z.; Chen, Z. Higher systemic immune-inflammation index is associated with higher likelihood of peripheral arterial disease. Ann. Vasc. Surg. 2022, 84, 322–326. [Google Scholar] [CrossRef] [PubMed]
  16. Xiang, J.; He, L.; Li, D.; Wei, S.; Wu, Z. Value of the systemic immune-inflammation index in predicting poor postoperative outcomes and the short-term prognosis of heart valve diseases: A retrospective cohort study. BMJ Open 2022, 12, e064171. [Google Scholar] [CrossRef]
  17. Urbanowicz, T.; Olasińska-Wiśniewska, A.; Gładki, M.; Jemielity, M. The Significance of Simple Inflammatory Markers in off Pump Surgery—Review. Rev. Cardiovasc. Med. 2022, 23, 400. [Google Scholar] [CrossRef]
  18. Russu, E.; Mureșan, A.V.; Arbănași, E.M.; Kaller, R.; Hosu, I.; Voidăzan, S.; Arbănași, E.M.; Coșarcă, C.M. The Predictive Role of NLR and PLR in Outcome and Patency of Lower Limb Revascularization in Patients with Femoropopliteal Disease. J. Clin. Med. 2022, 11, 2620. [Google Scholar] [CrossRef]
  19. Dey, S.; Kashav, R.; Kohli, J.K.; Magoon, R.; Shri, I.; Walian, A.; Grover, V. Systemic Immune-Inflammation Index Predicts Poor Outcome after Elective off-Pump CABG: A Retrospective, Single-Center Study. J. Cardiothorac. Vasc. Anesth. 2021, 35, 2397–2404. [Google Scholar] [CrossRef]
  20. Dogdus, M.; Dindas, F.; Yenercag, M.; Yildirim, A.; Abacioglu, O.O.; Kilic, S.; Yavuz, F.; Koyun, E.; Candan, O. The Role of Systemic Immune Inflammation Index for Predicting Saphenous Vein Graft Disease in Patients with Coronary Artery Bypass Grafting. The Role of Systemic Immune Inflammation Index for Predicting Saphenous Vein Graft Disease in Patients with Coronary Artery Bypass Grafting. Angiology 2022, 74, 579–586. [Google Scholar] [CrossRef]
  21. Hinoue, T.; Yatabe, T.; Nishida, O. Prediction of postoperative atrial fibrillation with the systemic immune-inflammation index in patients undergoing cardiac surgery using cardiopulmonary bypass: A retrospective, single-center study. J. Artif. Organs 2022, 26, 112–118. [Google Scholar] [CrossRef] [PubMed]
  22. Tosu, A.R.; Kalyoncuoglu, M.; Biter, H.I.; Cakal, S.; Selcuk, M.; Çinar, T.; Belen, E.; Can, M.M. Prognostic value of systemic immune-inflammation index for major adverse cardiac events and mortality in severe aortic stenosis patients after TAVI. Medicina 2021, 57, 588. [Google Scholar] [CrossRef] [PubMed]
  23. Zhang, Y.; Xing, Z.; Zhou, K.; Jiang, S. The Predictive Role of Systemic Inflammation Response Index (SIRI) in the Prognosis of Stroke Patients. Clin. Interv. Aging 2021, 16, 1997–2007. [Google Scholar] [CrossRef]
  24. Han, K.; Shi, D.; Yang, L.; Wang, Z.; Li, Y.; Gao, F.; Liu, Y.; Ma, X.; Zhou, Y. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Ann. Med. 2022, 54, 1667–1677. [Google Scholar] [CrossRef]
  25. Paliogiannis, P.; Ginesu, G.C.; Tanda, C.; Feo, C.F.; Fancellu, A.; Fois, A.G.; Mangoni, A.A.; Sotgia, S.; Carru, C.; Porcu, A.; et al. Inflammatory cell indexes as preoperative predictors of hospital stay in open elective thoracic surgery. ANZ J. Surg. 2018, 88, 616–620. [Google Scholar] [CrossRef] [PubMed]
  26. Szymanska, P.; Rozalski, M.; Wilczynski, M.; Golanski, J. Systemic immune-inflammation index (SII) and neutrophil to lymphocyte ratio (NLR) are useful markers for assessing effects of anti-inflammatory diet in patients before coronary artery bypass grafting. Rocz. Państwowego Zakładu Hig. 2021, 72, 327–335. [Google Scholar] [CrossRef]
  27. Şahin, A.; Sisli, E. Retrospective Evaluation of the Pre- and Postoperative Neutrophil-Lymphocyte Ratio as a Predictor of Mortality in Patients Who Underwent Coronary Artery Bypass Grafting. Heart Surg. Forum 2021, 24, E814–E820. [Google Scholar] [CrossRef]
  28. Sevuk, U.; Bilgic, A.; Altindag, R.; Baysal, E.; Yaylak, B.; Adiyaman, M.S.; Akkaya, S.; Ay, N.; Alp, V. Value of the neutrophil-to-lymphocyte ratio in predicting post-pericardiotomy syndrome after cardiac surgery. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 906–911. [Google Scholar]
  29. Urbanowicz, T.; Michalak, M.; Gąsecka, A.; Perek, B.; Rodzki, M.; Bociański, M.; Straburzyńska-Migaj, E.; Jemielity, M. Postoperative Neutrophil to Lymphocyte Ratio as an Overall Mortality Midterm Prognostic Factor following OPCAB Procedures. Clin. Pract. 2021, 11, 587–597. [Google Scholar] [CrossRef]
  30. Shao, Q.; Chen, K.; Rha, S.; Lim, H.; Li, G.; Liu, T. Usefulness of Neutrophil/Lymphocyte Ratio as a Predictor of Atrial Fibrillation: A Meta-analysis. Arch. Med. Res. 2015, 46, 199–206. [Google Scholar] [CrossRef] [PubMed]
  31. Moschonas, I.C.; Tselepis, A.D. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis 2019, 288, 9–16. [Google Scholar] [CrossRef] [Green Version]
  32. Döring, Y.; Libby, P.; Soehnlein, O. Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights. Circ. Res. 2020, 126, 1228–1241. [Google Scholar] [CrossRef] [PubMed]
  33. Jaipersad, A.S.; Lip, G.Y.H.; Silverman, S.; Shantsila, E. The Role of Monocytes in Angiogenesis and Atherosclerosis. J. Am. Coll. Cardiol. 2014, 63, 1–11. [Google Scholar] [CrossRef] [Green Version]
  34. Kim, K.W.; Ivanov, S.; Williams, J.W. Monocyte Recruitment, Specification, and Function in Atherosclerosis. Cells 2020, 10, 15. [Google Scholar] [CrossRef]
  35. Oksuz, F.; Elcik, D.; Yarlioglues, M.; Duran, M.; Ozturk, S.; Celik, I.E.; Kurtul, A.; Kilic, A.; Murat, S.N. The relationship between lymphocyte-to-monocyte ratio and saphenous vein graft patency in patients with coronary artery bypass graft. Biomark. Med. 2017, 11, 867–876. [Google Scholar] [CrossRef] [PubMed]
  36. Serra, R.; Ielapi, N.; Licastro, N.; Provenzano, M.; Andreucci, M.; Bracale, U.M.; Jiritano, F.; de Franciscis, S.; Mastroroberto, P.; Serraino, G.F. Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review. Rev. Recent Clin. Trials 2021, 16, 173–179. [Google Scholar] [CrossRef] [PubMed]
  37. Kurtul, A.; Ornek, E. Platelet to Lymphocyte Ratio in Cardiovascular Diseases: A Systematic Review. Angiology 2019, 70, 802–818. [Google Scholar] [CrossRef]
  38. Kounis, N.G.; Koniari, I.; Plotas, P.; Soufras, G.D.; Tsigkas, G.; Davlouros, P.; Hahalis, G. Inflammation, Thrombosis, and Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes. Angiology 2021, 72, 6–8. [Google Scholar] [CrossRef]
  39. Qiu, Z.; Jiang, Y.; Jiang, X.; Yang, R.; Wu, Y.; Xu, Y.; Cheng, X. Relationship between Platelet to Lymphocyte Ratio and Stable Coronary Artery Disease: Meta-Analysis of Observational Studies. Angiology 2020, 71, 909–915. [Google Scholar] [CrossRef]
  40. Camilli, M.; Iannaccone, G.; La Vecchia, G.; Cappannoli, L.; Scacciavillani, R.; Minotti, G.; Massetti, M.; Crea, F.; Aspromonte, N. Platelets: The point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Rev. Hematol. 2021, 14, 537–546. [Google Scholar] [CrossRef]
  41. Ibrahim, H.; Schutt, R.C.; Hannawi, B.; DeLao, T.; Barker, C.M.; Kleiman, N.S. Association of immature platelets with adverse cardiovascular outcomes. J. Am. Coll. Cardiol. 2014, 64, 2122–2129. [Google Scholar] [CrossRef] [Green Version]
  42. Nording, H.; Baron, L.; Langer, H.F. Platelets as therapeutic targets to prevent atherosclerosis. Atherosclerosis 2020, 307, 97–108. [Google Scholar] [CrossRef]
  43. Xu, X.R.; Zhang, D.; Oswald, B.E.; Carrim, N.; Wang, X.; Hou, Y.; Zhang, Q.; LaValle, C.; McKeown, T.; Marshall, A.H.; et al. Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit. Rev. Clin. Lab. Sci. 2016, 53, 409–430. [Google Scholar] [CrossRef]
  44. Wang, J.; Duan, Y.; Sluijter, J.P.; Xiao, J. Lymphocytic subsets play distinct roles in heart diseases. Theranostics 2019, 9, 4030–4046. [Google Scholar] [CrossRef]
  45. Duran, M.; Elçik, D.; Murat, S.; Öksüz, F.; Çelik, I.E. Risk factors for coronary artery disease in young patients with stable angina pectoris. Turk. J. Med. Sci. 2019, 49, 993–998. [Google Scholar] [CrossRef] [PubMed]
  46. De Somer, F. Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response during Cardiopulmonary Bypass. Recent Pat. Cardiovasc. Drug Discov. 2012, 7, 180–185. [Google Scholar] [CrossRef]
  47. Gokalp, O.; Yesilkaya, N.K.; Bozok, S.; Besir, Y.; Iner, H.; Durmaz, H.; Gokkurt, Y.; Lafci, B.; Gokalp, G.; Yilik, L.; et al. Effects of age on systemic inflamatory response syndrome and results of coronary bypass surgery. Cardiovasc. J. Afr. 2018, 29, 22–25. [Google Scholar] [CrossRef]
  48. Giacinto, O.; Satriano, U.; Nenna, A.; Spadaccio, C.; Lusini, M.; Mastroianni, C.; Nappi, F.; Chello, M. Inflammatory Response and Endothelial Dysfunction Following Cardiopulmonary Bypass: Pathophysiology and Pharmacological Targets. Recent Pat. Inflamm. Allergy Drug Discov. 2019, 13, 158–173. [Google Scholar] [CrossRef] [PubMed]
  49. Tanrıkulu, N.; Ozbek, B. Effects of cardiopulmonary bypass on dialysisdependent patients. Cardiovasc. J. Afr. 2019, 30, 275–278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Kolaczkowska, E.; Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 2013, 13, 159–175. [Google Scholar] [CrossRef]
  51. El-Benna, J.; Dang, P.M.; Gougerot-Pocidalo, M. Priming of the neutrophil NADPH oxidase activation: Role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin. Immunopathol. 2008, 30, 279–289. [Google Scholar] [CrossRef] [PubMed]
  52. Warren, O.J.; Smith, A.J.; Alexiou, C.; Rogers, P.L.; Jawad, N.; Vincent, C.; Darzi, A.W.; Athanasiou, T. The Inflammatory Response to Cardiopulmonary Bypass: Part 1—Mechanisms of Pathogenesis. J. Cardiothorac. Vasc. Anesth. 2009, 23, 223–231. [Google Scholar] [CrossRef] [PubMed]
  53. Ranucci, M.; Baryshnikova, E. Inflammation and coagulation following minimally invasive extracorporeal circulation technologies. J. Thorac. Dis. 2019, 11, S1480–S1488. [Google Scholar] [CrossRef]
  54. Demirtas, H.; Iriz, E.; Demirtas, C.Y.; Erer, D.; Oktar, L.; Yener, A.; Arslan, M. Investigating the effects of two different pump heads (Centrifugal vs. Roller Pump) on hematological and immunological mechanisms. Niger. J. Clin. Pract. 2018, 21, 847–853. [Google Scholar] [PubMed]
Life 13 01395 g001 550
Figure 1. ROC curves of systemic inflammation indices for lethal outcome. (A) SIRI, (B) SII, (C) AISI, (D) NLR, (E) PLR, (F) MLR.
Figure 1. ROC curves of systemic inflammation indices for lethal outcome. (A) SIRI, (B) SII, (C) AISI, (D) NLR, (E) PLR, (F) MLR.
Life 13 01395 g001
Table
Table 1. Clinical, instrumental, and laboratory characteristics of patients and their drug therapy before surgery.
Table 1. Clinical, instrumental, and laboratory characteristics of patients and their drug therapy before surgery.
ParametersValue (n = 363)
Age, years58.5 (44; 66.7)
Male, %221 (61)
BMI, kg/m227.8 (24.5; 30.9)
BSA, m20.2 (0.19; 0.21)
Hypertension, %134 (37)
Smoking, n (%)40 (11)
CHF NYHA class III-IV, n (%)134 (37)
Diabetes, n (%)25 (7)
COPD, n (%)7 (2)
CKD, n (%)14 (4)
Initial instrumental data
LVEF, %63 (58; 66)
iEDD2.6 (2.3; 3.0)
iESD1.7 (1.5; 1.9)
iEDV67.9 (51.7; 89.4)
iESV23 (18; 33)
Peak gradient, mm Hg90 (56; 107)
Mean gradient, mm Hg52 (42; 67)
Fibrous ring of the aortic valve, mm24 (22; 26)
LA volume, mL3104 (80; 133)
Initial laboratory data
Hemoglobin, g/L139 (128; 148)
Hematocrit, %42 (39; 44)
WBC, 109/L7.1 (5.9; 8.4)
Neutrophils, 109/L4.4 (3.6; 5.5)
Neutrophils, %60 (53; 65)
Glucose, mmol/L5.2 (4.8; 5.6)
Fibrinogen, g/L4.0 (3.5; 4.5)
Creatinine, mkmol/L80 (70; 94)
eGFR mL/min95 (77; 114)
eGFR mL/min per 1.73 m2 (MDRD)81 (71; 97)
Initial drug therapy
Beta-blockers, %41
ACE inhibitors, %29
ARA, %11
Calcium antagonists, %9
Statins, %20
Nitrates, %3
Thiazide diuretics, %9
Loop diuretics, %12
Potassium-sparing diuretics, %15
BMI—body mass index; BSA—body surface area; CHF NYHA—chronic heart failure New York Heart Association classification; COPD—chronic obstructive pulmonary disease; CKD—chronic kidney disease; LVEF—left ventricular ejection fraction; iEDD—index end diastolic diameter; iEDV—index end diastolic volume; iESD—index end systolic diameter; iESV—index end systolic volume; LA—left atrium; WBC—white blood cells; eGFR—estimated glomerular filtration rate; MDRD—modification of diet in renal disease; ACE—angiotensin-converting enzyme; ARA—angiotensin receptor antagonist.
Table
Table 2. Operative data of patients and hospital outcomes.
Table 2. Operative data of patients and hospital outcomes.
ParametersValue (n = 363)
Operative data
CPB time, min130 (113; 153)
ACC time, min65 (58; 76)
ICU time > 2 days, n (%)42 (11.6)
Clinical outcomes and complications
Mortality, n (%)7 (2)
AKI, n (%)47 (13)
POAF, n (%)36 (10)
Stroke/ACA, n (%)7 (2)
Bleeding, n (%)3 (0.8)
Length of stay, days7 (6; 8)
CPB—cardiopulmonary bypass; ACC—aortic cross-clamp; ICU—intensive care unit; AKI—acute kidney injury; POAF—postoperative atrial fibrillation; ACA—acute cerebrovascular accident.
Table
Table 3. Results of ROC analyses for quantitative values of systemic inflammation indices associated with the development of complications.
Table 3. Results of ROC analyses for quantitative values of systemic inflammation indices associated with the development of complications.
ParametersCut-Off PointAUC (CI)SeSpp
Death
SIRI >1.50.927 (0.891–0.954)10077.8<0.001 *
SII >7180.800 (0.750–0.844)66.785.10.002 *
AISI >5930.857 (0.812–0.896)66.794.3<0.001 *
NLR >2.480.884 (0.841–0.918)10073.1<0.001 *
PLR >1320.763 (0.716–0.806)71.473.20.004 *
MLR >0.3320.920 (0.886–0.947)10080.3<0.001 *
Acute kidney injury
SIRI >0.8980.549 (0.483–0.614)72.746.30.073
SII >3210.547 (0.481–0.611)87.9260.379
AISI >2430.568 (0.501–0.632)63.656.50.202
NLR >1.770.532 (0.467–0.597)72.741.50.535
PLR <92.60.489 (0.430–0.547)39.569.80.833
MLR <0.1330.498 (0.437–0.558)13.595.40.966
POAF
SIRI >1.20.532 (0.473–0.591)48.360.90.574
SII >5670.534 (0.475–0.592)44.869.50.589
AISI >3880.517 (0.457–0.575)3180.80.784
NLR >1.90.563 (0.504–0.620)72.444.90.281
PLR >1100.514 (0.461–0.567)57.9540.794
MLR >0.1820.513 (0.459–0.567)86.523.30.787
Stroke or ACA
SIRI >1.450.600 (0.513–0.682)66.772.60.685
SII >5530.556 (0.470–0.639)66.767.40.774
AISI >3370.593 (0.506–0.675)66.770.40.668
NLR >2.430.531 (0.446–0.616)66.766.70.892
PLR <1130.629 (0.556–0.698)10044.90.308
MLR >0.30.521 (0.445–0.597)66.768.60.921
Bleeding
SIRI >1.50.843 (0.771–0.900)10075<0.001 *
SII >4280.500 (0.414–0.586)10046.70.999
AISI >2310.616 (0.528–0.698)10048.50.391
NLR >2.80.766 (0.687–0.834)10075.9<0.001 *
PLR <1120.567 (0.493–0.639)10046.20.540
MLR >0.3920.904 (0.849–0.943)10088.9<0.001 *
AUC—area under curve; CI—confidence interval; Se—sensitivity; Sp—specificity; SIRI—systemic inflammation response index; SII—systemic inflammation index; AISI—aggregate inflammation systemic index; NLR—neutrophils lymphocytes ratio; PLR—platelets lymphocytes ratio; MLR—monocytes lymphocytes ratio; POAF—postoperative atrial fibrillation; ACA—acute cerebrovascular accident; *—statistically significant differences.
Table
Table 4. Uni- and multi-variate logistic regression analyses for a lethal outcome.
Table 4. Uni- and multi-variate logistic regression analyses for a lethal outcome.
ParametersUnivariate Logistic Regression Analysis OR (95% CI)pMultivariate Logistic Regression Analysis
OR (95% CI)		p
SIRI 1.143 (1.014–1.289)0.029 *2.533 (1.001–6.414)0.049 *
SII 1.003 (1.001–1006)0.015 *--
AISI 1.000 (1.000–1.001)0.042 *--
NLR 1.110 (1.025–1.203)0.011 *--
PLR 1.001 (1.000–1.002)0.068--
MLR 1.736 (0.980–3.073)0.058--
BMI ----
Hemoglobin, g/L0.957 (0.921–0.995)0.041 *--
Hematocrit, %0.895 (0.795–1.001)0.091--
CPB time, min1.021 (1.007–1.037)<0.001 *--
ACC time, min1.048 (1.029–1.075)<0.001 *1.046 (1.019–1.073)<0.001 *
Diabetes----
OR—odds ratio; CI—confidence interval; SIRI—systemic inflammation response index; SII—systemic inflammation index; AISI—aggregate inflammation systemic index; NLR—neutrophils lymphocytes ratio; PLR—platelets lymphocytes ratio; MLR—monocytes lymphocytes ratio; BMI—body mass index; CPB—cardiopulmonary bypass; ACC—aortic cross-clamp; *—statistically significant differences.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Shvartz, V.; Sokolskaya, M.; Ispiryan, A.; Basieva, M.; Kazanova, P.; Shvartz, E.; Talibova, S.; Petrosyan, A.; Kanametov, T.; Donakanyan, S.; et al. The Role of «Novel» Biomarkers of Systemic Inflammation in the Development of Early Hospital Events after Aortic Valve Replacement in Patients with Aortic Stenosis. Life 2023, 13, 1395. https://doi.org/10.3390/life13061395

AMA Style

Shvartz V, Sokolskaya M, Ispiryan A, Basieva M, Kazanova P, Shvartz E, Talibova S, Petrosyan A, Kanametov T, Donakanyan S, et al. The Role of «Novel» Biomarkers of Systemic Inflammation in the Development of Early Hospital Events after Aortic Valve Replacement in Patients with Aortic Stenosis. Life. 2023; 13(6):1395. https://doi.org/10.3390/life13061395

Chicago/Turabian Style

Shvartz, Vladimir, Maria Sokolskaya, Artak Ispiryan, Madina Basieva, Polina Kazanova, Elena Shvartz, Sayali Talibova, Andrey Petrosyan, Teymuraz Kanametov, Sergey Donakanyan, and et al. 2023. "The Role of «Novel» Biomarkers of Systemic Inflammation in the Development of Early Hospital Events after Aortic Valve Replacement in Patients with Aortic Stenosis" Life 13, no. 6: 1395. https://doi.org/10.3390/life13061395

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop